Pharmaceuticals

Tonix Pharmaceuticals' newly approved drug, TONMYA, offers a breakthrough for millions, using unique science to combat the chronic pain of fibromyalgia.

A new global survey reveals millions of women are unprepared for menopause's skin impact. One company is now pushing for a new standard in research.

New data on Idorsia's lucerastat reveals potential to slow kidney decline in Fabry disease, offering a new path for an oral, genotype-independent therapy.

With a Super Bowl ad, NFL icons like Rob Gronkowski and Novartis are demystifying prostate cancer screening to save lives. Relax, it's a blood test.

With its acquisition offer falling short of a majority, Cycle Pharma extends its tender for Applied Therapeutics, leaving the company's fate in the balance.

Industry leaders at the GenScript Global Forum agree: the era of AI experimentation is over. Now, the hard work of scaling and building trust begins.

A new report warns US drug price controls could mirror Canada's struggles, delaying access to new medicines. Is America trading innovation for affordability?

A German biotech's novel oral drug for herpes is moving to Phase 2 trials, offering new hope against a widespread and often resistant virus.

ENA Respiratory's INNA-051 nasal spray, a virus-agnostic shield, has begun Phase II trials, offering new hope for high-risk communities.

The Spanish pharma giant secures approval for the first oral antibiotic specifically for acne in China, targeting a multi-billion dollar dermatology market.

Alcami promotes a decade-long leader to COO, a strategic move to harness internal talent and manage its rapid growth in the booming CDMO market.

A new partnership marries AI design with high-throughput lab validation, creating a blueprint to accelerate the creation of new medicines.

As its promising prostate cancer drug nears Phase 3, Convergent Therapeutics hires a new CPO to build the team for its next critical growth phase.

BioBridges and its legacy brands consolidate into Peritia, a new end-to-end platform designed to accelerate product development for resource-strapped teams.

A new grant funds a radical approach using AI and postmortem human brains to find crucial clues for Parkinson's therapies, aiming to crack a major medical challenge.

As drug-resistant fungi pose a grave threat, SCYNEXIS presents promising data on SCY-247, a next-gen drug that could redefine the fight against infection.

With promising brain scan data, a deep therapeutic pipeline, and a cash runway into 2027, Radiopharm Theranostics is gaining significant momentum.

Stoke Therapeutics' major new lease in Waltham signals a pivotal shift to commercialization and defies a cooling life sciences real estate market.

Undercover footage shows disturbing treatment of beagles at a Toronto lab, sparking calls for investigation and questioning Canada's animal research laws.

Top scientists, survivors, and industry leaders are uniting to accelerate a new generation of cancer vaccines, moving them from lab to patient faster than ever.